Thbs1 Antibody

What is thrombospondin-1 (THBS1) and what are its main biological functions?

Thrombospondin-1 (TSP-1/THBS1) is an extracellular matrix glycoprotein originally identified as the first natural angiogenesis inhibitor. It functions as a molecular facilitator by bringing together cytokines, growth factors, matrix components, membrane receptors, and extracellular proteases . THBS1 is secreted by various cell types including endothelial cells, fibroblasts, adipocytes, smooth muscle cells, monocytes, macrophages, and transformed cells like malignant glioma cells . It plays significant roles in:

• Regulation of angiogenesis (primarily as an inhibitor)

• Cellular phenotype modulation during tissue genesis and repair

• Tumor progression and metastasis in multiple cancer types

• Immunomodulation, particularly in tumor microenvironments

• TGFβ activation (though data is contradictory between research groups)

What applications are THBS1 antibodies typically used for in research?

THBS1 antibodies have multiple validated research applications:

How should THBS1 antibody specificity be validated?

For proper validation of THBS1 antibody specificity, researchers should:

• Perform preabsorption controls by incubating the primary antibody with recombinant human THBS1 peptides at a molar ratio of 10:1 (antigen:antibody) at 4°C overnight

• Use the preabsorbed antibody alongside the regular antibody in immunostaining experiments

• Include negative controls by omitting the primary antibody

• Test reactivity against known positive control samples expressing THBS1 (e.g., HepG2 cells, rat spleen tissue, NIH/3T3 cells, Jurkat cells, K-562 cells)

• Verify detection at the expected molecular weight (observed ~160 kDa) in Western blot applications

How can THBS1 antibodies be used to study tumor invasion and metastasis?

THBS1 antibodies have proven valuable in investigating tumor invasion and metastasis through multiple experimental approaches:

• In vitro invasion assays: Studies show that neutralization of THBS1 with blocking antibodies targeting different epitopes can completely inhibit the invasive phenotype in cancer cells . Researchers can use collagen type I invasion assays with spheroids to quantify the impact of THBS1 neutralization .

• Orthotopic tumor models: THBS1 knockdown experiments complemented with antibody studies have demonstrated that THBS1 depletion leads to significant reduction in contra-lateral invasion (49-76% decrease) and increased survival in mouse models of glioblastoma .

• Vascular remodeling analysis: THBS1 antibodies can be used to investigate how THBS1 affects tumor vasculature. Studies show that THBS1-depleted tumors exhibit differences in vessel type distribution, with decreased small vessel numbers (<10 μm length) and increased medium-sized vessels (10-20 μm length) .

• Immune cell interaction studies: THBS1 antibodies can help study how THBS1 contributes to cytotoxic T-cell exhaustion in the tumor microenvironment, particularly in colorectal cancer models with mesenchymal characteristics .

What are the contradictions in research regarding THBS1's role in TGFβ activation?

Research on THBS1's role in TGFβ activation presents significant contradictions that researchers should be aware of when designing experiments with THBS1 antibodies:

When designing experiments to investigate THBS1-TGFβ interactions, researchers should:

• Test multiple cell lines

• Examine both TGFβ1 and TGFβ2 activation

• Use multiple readouts for TGFβ activation (e.g., SMAD phosphorylation, reporter assays, active TGFβ concentration measurements)

• Include appropriate controls with THBS1 knockdown or blocking antibodies

What epitopes are targeted by function-blocking THBS1 monoclonal antibodies and how does this affect their utility?

Function-blocking anti-THBS1 monoclonal antibodies target various epitopes throughout the THBS1 protein structure:

• Epitope distribution: Biological activities are present throughout the THBS1 molecule, including the EGF-like modules that were not previously implicated in function . Epitopes for at least 10 antibodies are likely within 18 nm of one another in calcium-replete THBS1 .

• Steric hindrance considerations: Some inhibitory effects may result from steric hindrance rather than direct binding to functional domains. For example, mAb133 binds the calcium-binding wire but can still interfere with the activation of latent TGFβ by the properdin modules through steric effects .

• Cross-reactivity mapping: When selecting antibodies for cross-species studies, researchers should consider that some anti-human THBS1 mAbs (like A4.1 and A6.1) recognize epitopes common to both human and mouse THBS1 . This mapping information is crucial for experimental design using animal models.

A systematic approach using a baculovirus expression system to produce individual modules or groups of modules spanning the human THBS1 molecule has helped map the epitopes of various antibodies, allowing more precise interpretation of which regions are responsible for different THBS1 activities .

How can THBS1 antibodies be used to study the role of THBS1 in cancer immunomodulation?

Recent research has revealed THBS1's significant role in cancer immunomodulation, particularly in colorectal cancer (CRC). THBS1 antibodies can be used to investigate these mechanisms:

• Cell source identification: Immunohistochemistry with THBS1 antibodies has demonstrated that bone marrow-derived monocyte-like cells recruited by CXCL12 are the primary source of THBS1 in the tumor microenvironment . This highlights the importance of studying immune cell-derived THBS1 rather than just tumor cell-derived THBS1.

• Mechanism of immunosuppression: THBS1 contributes to the development of metastasis by inducing cytotoxic T-cell exhaustion . Researchers can use THBS1 antibodies in flow cytometry or immunofluorescence studies to examine T-cell interactions with THBS1-producing cells.

• Therapeutic implications: In orthotopically generated CRC models, THBS1 loss in the tumor microenvironment renders tumors partially sensitive to immune checkpoint inhibitors and anti-cancer drugs . This suggests that combination studies with THBS1 antibodies and other immunotherapies could be valuable.

• CD47 interaction studies: THBS1 binds to CD47, and knockdown of CD47 significantly impairs THBS1-induced tumor cell invasion . Researchers can use THBS1 antibodies alongside CD47 manipulation to dissect this signaling axis.

What are the technical considerations for using THBS1 antibodies in hypoxia studies?

Hypoxia has been shown to induce THBS1 expression , making THBS1 antibodies valuable tools for studying tumor hypoxia responses. Technical considerations include:

• Indirect mechanisms: Despite the hypoxia-THBS1 connection, no HIF1α binding sequence is present in the THBS1 promoter . Instead, hypoxia leads to TGFβ1 activation and nuclear accumulation of Smad transcription factors, which then induce THBS1 expression .

• Experimental design: When studying hypoxic regulation of THBS1, researchers should:

  • Include both HIF1α and TGFβ signaling pathway analyses

  • Monitor Smad3 activation, as it has been demonstrated to induce THBS1 expression

  • Use appropriate time points, as THBS1 induction may be a secondary response to hypoxia

  • Consider that hypoxia-induced THBS1 may contribute to bevacizumab resistance in tumors

• Anti-angiogenic therapy studies: THBS1 inhibition reinforces the effect of anti-angiogenic treatments like bevacizumab . Researchers can use THBS1 antibodies to study how blocking THBS1 might enhance response to anti-angiogenic therapies.

What dilutions and protocols are recommended for THBS1 antibody applications?

Based on validated antibody products, the following dilutions are typically recommended:

Storage recommendations:

• Store at -20°C

• Stable for one year after shipment

• Aliquoting may be unnecessary for -20°C storage

How should researchers design THBS1 neutralization experiments?

When designing THBS1 neutralization experiments, researchers should consider:

• Multiple epitope targeting: Use multiple blocking antibodies targeting different epitopes of the THBS1 protein to exclude any potential non-specific binding effects . This approach has been shown to completely block THBS1-induced phenotypes in experimental models.

• Appropriate controls: Include isotype-matched control antibodies (e.g., IgG1) in parallel experiments .

• Functional readouts: When studying THBS1 neutralization, include multiple functional readouts such as:

  • Morphological changes in 3D culture systems

  • Proliferation assays (e.g., counting proliferative cells per organoid)

  • Invasion assays in collagen matrices

  • Angiogenesis assays looking at endothelial cell invasion and capillary formation

• Dosage optimization: Titrate antibody concentrations to determine optimal neutralization while minimizing off-target effects.

How can researchers resolve contradictory findings with THBS1 antibodies?

When faced with contradictory findings using THBS1 antibodies:

• Epitope consideration: Different antibodies targeting different THBS1 domains may yield contradictory results. Map the epitopes of the antibodies used and consider how this might affect interpretation .

• Cell type differences: Results may vary between cell lines. For example, the U87 cell line responses may differ from patient-derived tumor cells . Test multiple cell lines or primary cells when possible.

• Species variations: Consider species differences in THBS1 structure and function. Some antibodies cross-react between human and mouse THBS1, while others do not .

• Experimental conditions: THBS1 function can be context-dependent. For instance, TGFβ1 stimulation increases THBS1 expression in a time-dependent manner in multiple cell lines, but TGFβ2, EGF, PDGF-BB, or IL-1β stimulation does not .

• Calcium dependency: THBS1 conformation is calcium-dependent, which may affect antibody binding and function. Consider calcium conditions in experimental buffers .

By systematically addressing these factors, researchers can better understand and resolve contradictory findings when using THBS1 antibodies in their research.